000117357 001__ 117357
000117357 005__ 20240705134134.0
000117357 0247_ $$2doi$$a10.3390/diagnostics11122323
000117357 0248_ $$2sideral$$a127001
000117357 037__ $$aART-2021-127001
000117357 041__ $$aeng
000117357 100__ $$aHijos-Mallada G.
000117357 245__ $$aA patient self-made point-of-care fecal test improves diagnostic accuracy compared with fecal calprotectin alone in inflammatory bowel disease patients
000117357 260__ $$c2021
000117357 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117357 5203_ $$aBackground: Monitoring inflammatory bowel disease patients may be challenging. Fecal calprotectin is one of the most performed tests. Other fecal biomarkers are less used in clinical practice. Rapid fecal tests that could be performed by patients may be a useful strategy to closely monitor disease activity. Methods: We performed a prospective observational study including consecutive inflammatory bowel disease patients referred for colonoscopy in a single center. Certest FOB + Transferrin + Calprotectin + Lactoferrin® (Certest Biotec S.L, Zaragoza, Spain), a one-step point-of-care test which simultaneously detects these four biomarkers was performed. Endoscopic inflammatory activity was defined using the Mayo score (=1) in ulcerative colitis, SES-CD (>3) and Rutgeerts scores (=1) for Crohn’s disease. Results: Out of a total of 106 patients (56.5% female, mean age 51 years), 54 (50.9%) were diagnosed with ulcerative colitis and 52 (49.1%) with Crohn’s disease. Endoscopic activity was detected in 42 patients (39.0%). Fecal calprotectin provided the best sensitivity (97.6%), with limited specificity (34.4%). Compared to calprotectin, the other 3 fecal biomarkers showed better specificity (87.5–92.1%) and lower sensitivity (45.2–59.5%). Patients with a negative result in all biomarkers (19/106—17.9%) had 100% (CI 95% 97.4–100) negative predictive value, while patients with the 4 biomarkers positive (13/106—12.3%) had 100% (CI 95% 96.1–100) positive predictive value of endoscopic inflammatory activity. AUROC of this 4 biomarker point-of-care test was 0.845 (95% CI 0.771–0.920), significantly higher than the AUROCs of any of the 4 biomarkers. Conclusions: This test may be a useful strategy to monitor inflammatory activity in clinical practice by excluding or prioritizing patients in need of a colonoscopy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000117357 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-01109
000117357 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117357 590__ $$a3.992$$b2021
000117357 592__ $$a0.658$$b2021
000117357 594__ $$a2.4$$b2021
000117357 591__ $$aMEDICINE, GENERAL & INTERNAL$$b60 / 172 = 0.349$$c2021$$dQ2$$eT2
000117357 593__ $$aClinical Biochemistry$$c2021$$dQ2
000117357 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117357 700__ $$aVelamazán R.
000117357 700__ $$aMarti R.
000117357 700__ $$aChueca E.
000117357 700__ $$aArechavaleta S.
000117357 700__ $$aLué A.
000117357 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón F.$$uUniversidad de Zaragoza
000117357 700__ $$0(orcid)0000-0001-5932-2889$$aLanas A.$$uUniversidad de Zaragoza
000117357 700__ $$aSostres C.
000117357 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000117357 773__ $$g11, 12 (2021), 2323 [10 pp]$$tDiagnostics$$x2075-4418
000117357 8564_ $$s866639$$uhttps://zaguan.unizar.es/record/117357/files/texto_completo.pdf$$yVersión publicada
000117357 8564_ $$s2808259$$uhttps://zaguan.unizar.es/record/117357/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117357 909CO $$ooai:zaguan.unizar.es:117357$$particulos$$pdriver
000117357 951__ $$a2024-07-05-12:45:17
000117357 980__ $$aARTICLE